Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 6:3:10.
doi: 10.1186/2047-1440-3-10. eCollection 2014.

Systematic review of melanoma incidence and prognosis in solid organ transplant recipients

Affiliations
Review

Systematic review of melanoma incidence and prognosis in solid organ transplant recipients

Erin Dahlke et al. Transplant Res. .

Abstract

Cutaneous melanoma carries the potential for substantial morbidity and mortality in the solid organ transplant population. We systematically reviewed the literature published from January 1995 to January 2012 to determine the overall relative risk and prognosis of melanoma in transplant recipients. Our search identified 7,512 citations. Twelve unique non-overlapping studies reported the population-based incidence of melanoma in an inception cohort of solid organ transplant recipients. Compared to the general population, there is a 2.4-fold (95% confidence interval, 2.0 to 2.9) increased incidence of melanoma after transplantation. No population-based outcome data were identified for melanoma arising post-transplant. Data from non-population based cohort studies suggest a worse prognosis for late-stage melanoma developing after transplantation compared with the general population. For patients with a history of pre-transplant melanoma, one population-based study reported a local recurrence rate of 11% (2/19) after transplantation, although staging and survival information was lacking. There is a need for population-based data on the prognosis of melanoma arising pre- and post-transplantation. Increased incidence and potentially worse melanoma outcomes in this high-risk population have implications for clinical care in terms of prevention, screening and reduction of immunosuppression after melanoma development post-transplant, as well as transplantation decisions in patients with a history of pre-transplant melanoma.

Keywords: Cancer; Epidemiology; Incidence; Malignancy; Melanoma; Neoplasia; Prognosis; Registry; Transplant.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram.
Figure 2
Figure 2
Forest plot of standardized incidence ratios for 12 included studies. CI, confidence interval; SIR, standardized incidence ratio.

Similar articles

Cited by

References

    1. Sheil AG. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc. 1992;24(4):1275–1279. - PubMed
    1. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67(8):1167–1198. doi: 10.2165/00003495-200767080-00006. - DOI - PubMed
    1. Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154(3):498–504. doi: 10.1111/j.1365-2133.2005.07021.x. - DOI - PubMed
    1. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10(8):1889–1896. doi: 10.1111/j.1600-6143.2010.03181.x. - DOI - PubMed
    1. Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sorensen HT. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol. 2010;90(5):474–479. doi: 10.2340/00015555-0919. - DOI - PubMed

LinkOut - more resources